Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/10/2017 08/11/2017 08/14/2017 08/15/2017 08/16/2017 Date
75.94(c) 78.22(c) 79.64(c) 80.37(c) 81.35(c) Last
2 078 591 847 539 617 460 499 743 587 004 Volume
-5.69% +3.00% +1.82% +0.92% +1.22% Change
More quotes
Financials ($)
Sales 2017 78,9 M
EBIT 2017 -470 M
Net income 2017 -466 M
Finance 2017 494 M
Yield 2017 -
Sales 2018 119 M
EBIT 2018 -494 M
Net income 2018 -490 M
Finance 2018 384 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 88,4x
EV / Sales2018 59,4x
Capitalization 7 463 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined... 
Sector
Biotechnology & Medical Research
Calendar
08/23 | 09:30pmSpecial Situation
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
08/15 Three CEOs resign from Trump council over Charlottesville
08/09 ALNYLAM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
08/09 ALNYLAM PHARMACEUTICALS : reports 2Q loss
08/09 ALNYLAM PHARMACEUTICALS, INC. (NASDA : ALNY) Files An 8-K Results of Operations ..
08/09 ALNYLAM PHARMACEUTICALS : Reports Second Quarter 2017 Financial Results and High..
08/09 ALNYLAM PHARMACEUTICALS, INC. : Investor Network: Alnylam Pharmaceuticals, Inc t..
08/03 ALNYLAM PHARMACEUTICALS : to Host Fourth Annual "RNAi Roundtable" Webcast Series
08/01 ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing Second Quarter 2..
07/27 ALNYLAM PHARMACEUTICALS : to Host Fourth Annual “RNAi Roundtable” We..
07/11 ALNYLAM PHARMACEUTICALS, INC. : Today's Research Reports on Stocks to Watch: Aln..
More news
Sector news : Biotechnology & Medical Research - NEC
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
07/31 France's Sanofi raises earnings forecast, pleased with eczema drug uptake
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
06:23aAlnylam Pharmaceuticals $ALNY Earns Daily Media Sentiment Score of 0.14  
08/16Q2 #Earnings Wrap-Up, Remaining Q3 Milestones In Focus $INSM $OTIC $ALNY $ZYN.. 
08/16$FGEN $326M follow-on continues massive #biopharma equity raises this yr; oth..
2
08/1551,100 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Renaissance .. 
08/15Q2 #Earnings Wrap-Up, Remaining Q3 Milestones In Focus $INSM $OTIC $ALNY $ZYN.. 
More tweets
Qtime:38
News from SeekingAlpha
08/14 Alnylam Shoots For The Moon With Apollo
08/10 Alnylam Pharmaceuticals' (ALNY) Investigation Of Mortality Imbalance In Revus..
08/10 Looking Beyond Factors In Hemophilia
08/10 Alnylam Pharmaceuticals (ALNY) Q2 2017 Results - Earnings Call Transcript
08/09 Alnylam Q2 loss widens; APOLLO data nears
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Technical analysis trends ALNYLAM PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 89,0 $
Spread / Average Target 9,4%
EPS Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne L. Greenstreet Chief Operating Officer & Executive Vice President
Manmeet Singh Soni Chief Financial Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.112.71%7 463
INCYTE CORPORATION26.03%25 995
QUINTILES IMS HOLDINGS INC18.33%19 819
LONZA GROUP37.66%17 539
CELLTRION, INC.--.--%11 245
ALKERMES PLC-7.12%7 929